Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology Cohort

描述（由申请人提供）：我们建议加强亚投行基础设施建设；社区动脉粥样硬化风险，队列产生一个新的癌症流行病学队列，为癌症流行病学研究带来新的特点。1987年，从北卡罗来纳州福赛斯公司招募了15,792名年龄在45-64岁之间的参与者；杰克逊女士;明尼阿波利斯、锰;在马里兰州的华盛顿，55%是女性，27%是非洲裔美国人。参与者进行了4次临床检查；第五次计划于2011年进行。血液和尿液标本已储存，药物记录，并完成了食物频率问卷调查。参与者每年进行一次电话访谈，现在每半年进行一次，以获取最新的健康信息。第21年的应答率为91%。由于ARIC从未被视为癌症流行病学队列以及基础设施和成本限制，只有癌症诊断被系统地记录下来。到2006年，3145名参与者被诊断为第一次原发性心脏病，376名被诊断为第二次或第三次原发性心脏病。诸如分期、分级、组织学、器官位置、侧边、受体状态、治疗、复发和再治疗等信息，目前还没有解决当代问题所需的信息。分子/遗传研究所需的组织尚未收集。因此，我们建议：1)从2012年开始，从半年一次的电话访谈中前瞻性地确定病例，并收集有关癌症诊断、治疗、复发、再治疗和组织阻塞的医疗/病理记录。2)回顾性收集4个ARIC国家癌症登记处（已获得同意）和医疗记录中2012年前癌症诊断和复发的特征信息，并收集组织块。到2016年，我们预计将有4900个完整注释的事件案例。我们建立了一个癌症工作组，以制定癌症终点的裁决协议，并优先考虑使用该资源的研究。随着基础设施的增强，我们期望这些研究问题在ARIC中得到独特的解决：1)使用4次空腹血糖和2次HbAlc测量糖尿病自然病史的时间与癌症诊断的时间之间有何关联？2)使用GWAS和测序数据，主要癌症是否存在一组共同的风险变异，还是每个位点都有特定的变异？

DESCRIPTION (provided by applicant): We propose to enhance the infrastructure of ARIC; the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; Minneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, and histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing of the natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site?